ertheless, the implications of Gleason score are less clear in black men because of disparate prostate cancer outcomes, particularly for Gleason 6 disease, in which risk assessment and management of disease in black men is controversial. 2, 3 We investigated prostate cancer-specific mortality by Gleason score and race.
Methods | The Surveillance, Epidemiology, and End Results (SEER) Prostate Active Surveillance/Watchful Waiting (AS/WW) database identified men diagnosed as having and nonblack patients (1361 of 160 383 [0.85%]) (aHR, 1.10; 95% CI, 0.96-1.25; P = .17) in the cohort. However, black patients with Gleason 6 disease had a higher risk of prostate cancer death compared with nonblack patients (aHR, 1.95; 95% CI, 1.42-2.67; P < .001), while no significant difference was observed with Gleason 7 to 10 disease (aHR, 1.01; 95% CI, 0.87-1.16; P = .94) (P<.001 for interaction) (Figure and Table) . All covariates were significantly associated with prostate cancer death, including favorable associations with AS/WW and increasing SES (Table) .
Similar findings were observed in 403 022 patients with a longer median follow-up of 65 months (62 736 black; 340 286 nonblack); racial disparities between black patients vs nonblack patients were greatest in Gleason 6 disease (12-year prostate cancer mortality rate, 2.2% vs 1.4%) compared with Gleason 7 to 10 disease (12-year prostate cancer mortality rate, 5.5% in black patients vs 5.3% in nonblack patients) (P<.001 for interaction) (Table) .
Discussion | Racial disparities were greatest in low-grade Gleason 6 disease, in which black men were twice as likely to die of prostate cancer compared with nonblack men. Although absolute rates of prostate cancer death were small after short follow-up, disparities were greater at 12 years in a cohort with longer follow-up. In contrast to previous analyses, 5 the SEER AS/WW database allowed adjustments for SES and AS/WW, thereby better controlling for socioeconomic and treatment selection differences and supporting the hypothesis that low-grade prostate cancer may be distinct in black men. 6 Other potential contributors include racial differences in patient characteristics, prognostic value of biopsy, and patterns of care. Ultimately, these findings demonstrate the need to further study and characterize low-grade disease in black men. This study was limited by short follow-up and possible unadjusted confounding variables. Future studies with longer follow-up will be needed to further characterize low-grade disease in black men and to determine the clinical significance of the small absolute differences and whether they continue to increase over time.
